The Food and Drug Administration has granted accelerated approval to pembrolizumab for adult and paediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). Approval was based on Cancer Immunotherapy Trials Network...
Original Article: FDA approves pembrolizumab for Merkel cell carcinoma